WESTON,
Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex
Pharmaceuticals, Inc., a clinical stage pharmaceutical company
focused on developing transformative therapies for cancer and other
life-threatening medical conditions for which new treatments are
urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer,
will participate in the BIO CEO & Investor Conference being
held February 26-27, 2024 in
New York City.
During the conference, Dr. Marcus will conduct one-on-one
meetings with registered investors, showcasing the Company's
business and clinical development strategy, recent corporate
achievements, and anticipated milestones. Cantex is developing
azeliragon, an oral inhibitor of the receptor for advanced
glycation end products (known as RAGE). Cantex has ongoing Phase 2
clinical trials in top US and EU medical centers in glioblastoma,
brain metastasis, metastatic pancreatic cancer, and breast cancer,
and a Phase 3 randomized, placebo-controlled clinical trial in
hospitalized patients with pneumonia.
Details of the event are as follows:
|
Event:
|
BIO CEO &
Investor Conference
|
|
Date &
Time:
|
February 26-27,
2024
|
|
Location:
|
The New York Marriott
Marquis, New York, NY
|
|
Registration:
|
https://bcic.bio.org/registration
|
About Azeliragon
Azeliragon is an orally administered capsule, taken once daily,
that inhibits interactions of the receptor for advanced glycation
end products (known as RAGE) with certain ligands, including HMGB1
and S100 proteins in the tumor microenvironment. Azeliragon was
discovered by and originally under development for Alzheimer's
disease by vTv Therapeutics Inc. (NASDAQ: VTVT), from which Cantex
licensed worldwide rights to azeliragon. Clinical safety data from
these trials, involving more than 2,000 individuals dosed for
periods up to 18 months, indicate that azeliragon is very well
tolerated.
Cantex has multiple ongoing clinical trials as noted above.
These trials are based on azeliragon's robust preclinical data as
well as its extensive clinical safety information from randomized
placebo-controlled clinical trials.
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a privately held, clinical stage
pharmaceutical company focused on developing transformative
therapies for cancer and other life-threatening medical conditions
for which new treatments are urgently needed. For more information,
please visit www.cantex.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical stage biopharmaceutical
company focused on developing oral, small molecule drug candidates,
led by cadisegliatin (TTP399), a potentially transformative
treatment for the reduction of hypoglycemic episodes in type 1
diabetes patients. To learn more please visit
vtvtherapeutics.com.
Contact Data:
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
+1 862-213-1398
dboateng@tiberend.com
Media
Casey McDonald
+1 646-577-8520
cmcdonald@tiberend.com
Cantex Pharmaceuticals, Inc.
Stephen G. Marcus, M.D.
+1 954-315-3660
info@cantex.com
Juan F. Rodriguez
+1 954-315-3660
info@cantex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-to-participate-in-the-bio-ceo--investor-conference-302069258.html
SOURCE Cantex Pharmaceuticals, Inc.